{
    "guideline_id": "2024CSCO肿瘤患者静脉血栓防治指南- .txt",
    "cancer_info": {
        "cancer_name": "Cancer-Associated Thrombosis"
    },
    "clinical_recommendations": [
        {
            "clinical_context": "VTE risk assessment in medical/outpatient cancer patients",
            "recommendation_type": "Screening",
            "recommendation_content": "Use Khorana score (≥2 points indicates high risk)",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "VTE risk assessment in surgical cancer patients",
            "recommendation_type": "Screening",
            "recommendation_content": "Use Caprini score (≥3 points requires prophylaxis)",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "VTE risk assessment in multiple myeloma patients",
            "recommendation_type": "Screening",
            "recommendation_content": "Use China MM risk stratification system (≥9 points indicates high risk)",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Diagnosis of suspected DVT",
            "recommendation_type": "Diagnosis",
            "recommendation_content": "Direct lower extremity compression ultrasound without D-dimer screening",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Diagnosis of suspected PE",
            "recommendation_type": "Diagnosis",
            "recommendation_content": "CT pulmonary angiography (CTPA); bedside echocardiography for high-risk cases",
            "treatment_line": "",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Preventive anticoagulation for high-risk medical patients",
            "recommendation_type": "Prevention",
            "recommendation_content": "LMWH or UFH",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "1A"
        },
        {
            "clinical_context": "Preventive anticoagulation for high-risk medical patients",
            "recommendation_type": "Prevention",
            "recommendation_content": "Rivaroxaban 10mg daily or Apixaban 2.5mg twice daily",
            "treatment_line": "Second-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level II Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Preventive anticoagulation for surgical patients",
            "recommendation_type": "Prevention",
            "recommendation_content": "LMWH/UFH starting 12h pre-op, continuing 7-10 days post-op",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "1A"
        },
        {
            "clinical_context": "Preventive anticoagulation for pelvic cancer surgery",
            "recommendation_type": "Prevention",
            "recommendation_content": "Apixaban 2.5mg twice daily",
            "treatment_line": "Second-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level II Recommendation",
            "evidence_level": ""
        },
        {
            "clinical_context": "Preventive anticoagulation for high-risk multiple myeloma",
            "recommendation_type": "Prevention",
            "recommendation_content": "Therapeutic-dose LMWH or Rivaroxaban",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "1A"
        },
        {
            "clinical_context": "Treatment of acute DVT/PE without contraindications",
            "recommendation_type": "Treatment",
            "recommendation_content": "LMWH/fondaparinux ≥5 days → transition to rivaroxaban/apixaban/edoxaban ≥6 months",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "1A"
        },
        {
            "clinical_context": "Treatment of high-risk PE",
            "recommendation_type": "Treatment",
            "recommendation_content": "Thrombolysis (rtPA) or thrombectomy",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "1A"
        },
        {
            "clinical_context": "Treatment of catheter-related thrombosis",
            "recommendation_type": "Treatment",
            "recommendation_content": "Anticoagulation ≥3 months without routine catheter removal",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "1A"
        },
        {
            "clinical_context": "Treatment in renal impairment (CrCl<30ml/min)",
            "recommendation_type": "Treatment",
            "recommendation_content": "UFH or dose-adjusted DOAC",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "1A"
        },
        {
            "clinical_context": "Treatment in thrombocytopenia (PLT<50×10⁹/L)",
            "recommendation_type": "Treatment",
            "recommendation_content": "Platelet transfusion followed by anticoagulation",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "1A"
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "D-dimer demonstrates high negative predictive value for VTE exclusion. Cardiac biomarkers (troponin, BNP/NT-proBNP) enable risk stratification in pulmonary embolism. Genetic biomarkers (antithrombin, protein C/S) identify inherited thrombophilia in selected populations."
    },
    "tcm_recommendations": []
}